Market context: Regulatory volatility meets deal resilience

Accelerated Approval confirmatory trials requirement may further complicate life science deals

DOJ Secures First of Its Kind Cybersecurity False Claims Act Settlement

Life Science & Healthcare Private Capital Risk: Q2 2025 Update

New EU Responsibility and Liability Landscape for Smart Medical Devices in a Global Context

DOJ and HHS Relaunch False Claims Act Working Group, Sharpen Healthcare Enforcement Priorities

AI’s Expanded Role in the Life Sciences Regulatory Review Process: Key Developments in U.S. and EU

FDA Foreign Inspections: Key developments and strategic shifts

Life Science Private Equity Risk